Understanding resistance to antibody-drug conjugates in lung cancer treatment

31 Просмотры

  • Спасибо! Поделитесь с друзьями!

    Вам не понравилось видео. Спасибо за то что поделились своим мнением!

admin
Издатель
Samreen Ahmed, FRCP, MD, MBBS, MSc, University Hospitals of Leicester NHS Trust, Leicester, UK, discusses her presentation on antibody-drug conjugate (ADC) resistance at BTOG 2025. Drawing from her experience in breast cancer treatment, where ADCs have been widely used, she explores how insights from HER2-targeted therapies can inform lung cancer management. Her talk highlighted the evolving understanding of resistance mechanisms and their implications for future treatment strategies. This interview took place at the BTOG 2025 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Категория
Рак Молочной Железы
Комментариев нет.

Следующее